Ampersand Capital Partners, a middle-market private equity firm, completed the investment in Julius Clinical Research, an academic research organization. Financial terms were not disclosed. "Julius Clinical Research is extremely pleased to have secured the support of Ampersand to help expand our expertise and geographic reach as a global research and scientific partner to pharmaceutical and biotechnology companies. We’ve been on a growth journey at Julius Clinical, driven by a combination of world-class scientific expertise and clinical study execution skills,” Martijn Wallert, Julius Clinical CEO.